Deutsche Bank Starts Teva Pharma (TEVA) at Buy
- Hold on Tight... Fed Day Could Bring a Number of Changes
- Pre-Open Stock Movers 9/17: (AUXL) (IMUC) (X) Higher; (RAX) (SNE) (ADBE) Lower (more...)
- FedEx (FDX) Tops Q1 EPS by 14c
- Peltz's Trian to Meet with DuPont (DD) Holders
- Microsoft (MSFT) Announces Board Changes; Boosts Qtr. Dividend 11% to 31c/Share
Deutsche Bank initiated coverage on Teva Pharma (NYSE: TEVA) with a Buy rating and a price target of $63.00.
Analyst Gregg Gilbert said, "While the potential cliff for Copaxone looms and the generics business has not been without challenges, we like the combination of valuation, attractive dividend yield (similar to Big Pharma), and the potential for greater focus on strategic initiatives that increase shareholder value under new CEO Erez Vigodman. We see the recent hire of industry veteran Siggi Olafsson to run global generics and the simplification of the management structure as positive steps, and we sense that investors are skeptical about cost savings initiatives, the entire branded product pipeline, and Teva’s ability/desire to do deals."
Shares of Teva Pharma closed at $54.95 yesterday.
You May Also Be Interested In
- Goldman Sachs Starts GrubHub Inc. (GRUB) at Neutral
- BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Demonstrates the Safety and Efficacy of OpRegen® in Preclinical Animal Studies
- KeyBanc Starts Dresser-Rand Group (DRC) at Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, New Coverage
Related EntitiesDeutsche Bank, Dividend
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!